Changes in body weight and body composition in patients with active rheumatoid arthritis aged 65+ treated with 2-year low-dose add-on prednisolone in the randomised double-blind placebo-controlled GLORIA trial
Primary result · Change in body weightResult — go to the resultDifference 1.3 CI 0.5–2.2Authors' conclusion
Patients with active RA aged 65+ treated with prednisolone 5 mg/day for 2 years gained about 1 kg in weight, compared with minimal-non-significant-weight loss on placebo.
Study context
- Population
- Patients with active rheumatoid arthritis (RA) aged 65+57 with DXA body composition
- Participants
- 449 patients
- Comparison
- Prednisolone 5 mg/day added to standard care for 2 years vs placebo
- Primary endpoint
- Change in body weight
- Follow-up
- 2 years
Methodological detailspragmatic, placebo-controlled, double-blind, longitudinal mixed models
- Pragmatic
- Placebo-controlled
- Double-blind
- Longitudinal mixed models
Primary result
As reported in the abstract
Difference
1.3
CI 0.5–2.2
P < 0.01
Change by group
Prednisolone
0.9
mean · 95% CI 0.3–1.6 · kg
Placebo
−0.4
mean · 95% CI −1.1–0.2 · kg
Prednisolonevs Placebo
difference 1.3 (CI 0.5–2.2); P < 0.01
Further findings
Relation with disease activity
- Treatment effect independent of disease activity suppression
Body composition (DXA) · 2 years
- Treatment effect comprised mostly increase in (appendicular) lean mass
- No significant increase in total fat mass, nor redistribution of fat mass from peripheral to central tissues
Original publication
Changes in body weight and body composition in patients with active rheumatoid arthritis aged 65+ treated with 2-year low-dose add-on prednisolone in the randomised double-blind placebo-controlled GLORIA trial. RMD Open. Published 22 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →